GCP Inspection of Ti Trial Master Files



Similar documents
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes

Reflection paper on GCP compliance in relation to trial master files (paper and/or electronic) for management, audit and inspection of clinical trials

RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING

GCP - Records Managers Association

GCP INSPECTORS WORKING GROUP <DRAFT> REFLECTION PAPER ON EXPECTATIONS FOR ELECTRONIC SOURCE DOCUMENTS USED IN CLINICAL TRIALS

Signature Requirements for the etmf

Archiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist

An Overview of Clinical Archiving. Russell Joyce Records & Information Manager

Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials

STANDARD OPERATING PROCEDURE FOR RESEARCH. Management of Essential Documents and Trial Folders

Safeguarding public health The Regulation of Software as a Medical Device

Managing & Validating Research Data

Metrics 101. Produced by the TMF Reference Model Metrics and Reporting Sub-team. 1 August 2014

Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL

What is necessary to provide good clinical data for a clinical trial?

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples

Introduction The Role of Pharmacy Within a NHS Trust Pharmacy Staff Pharmacy Facilities Pharmacy and Resources 6

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

Trial Delivery SOP 05 Trial Archiving

This SOP may also be used by staff from other NHS areas, or organisations, with prior agreement.

Points to Consider When Developing a TMF (Trial Master File) Strategy

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

gsop Vendor Assessment SOP page 1 of 10

TRIAL MASTER FILE- SPONSORED

DATA MANAGEMENT IN CLINICAL TRIALS: GUIDELINES FOR RESEARCHERS

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015

UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE

Emerging Device Topics for Regulatory Consideration.. Janine Jamieson May 2015

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd

Archiving Study Documents

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program

Archiving of Research Documentation

Standard Operating Procedure for Archiving Essential Documentation relating to Clinical Trials of Investigational Medicinal Products (CTIMPs)

This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled.

Computerised Systems. Seeing the Wood from the Trees

EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE

CONTROLLED DOCUMENT- DO NOT COPY STANDARD OPERATING PROCEDURE. STH Investigator

Food supplements. Summary information on legislation relating to the sale of food supplements

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015

UK Implementation of the EU Clinical Trial Directive 2001/20/EC:

CONTROLLED DOCUMENT. Uncontrolled Copy. RDS014 Research Related Archiving. University Hospitals Birmingham NHS Foundation Trust

A 15-MINUTE GUIDE TO CLINICAL TRIAL DOCUMENT MANAGEMENT AND THE etmf

COMMISSION DIRECTIVE 2003/94/EC

Clinical Research in Mauritius

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Clinical database/ecrf validation: effective processes and procedures

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)

Research Study Close-down and Archiving Procedures

SOP Number: SOP-QA-20 Version No: 1. Author: Date: (Patricia Burns, Research Governance Manager, University of Aberdeen)

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International

FDA Regulation of Electronic Source Data in Clinical Investigations

Adoption by GCP Inspectors Working Group for consultation 14 June End of consultation (deadline for comments) 15 February 2012

Trial Master File Reference Model User Guide V 1.0

Guidance to Research Ethics Committees on Initial Facility Assessment

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

Essential Documentation and the Creation and Maintenance of Trial Master Files

Guidance for Industry

Reflection paper on the Use of Interactive Response Technologies (Interactive Voice/Web Response Systems) in Clinical Trials

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials

GE02-H I. Archiving of Clinical Trial Documents

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

Office for Nuclear Regulation

JRO RMG RSS SOP 12. Standard Operating Procedure (SOP) for Study Closedown and Archiving Royal Free site specific SOP

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

Document Number: SOP/RAD/SEHSCT/007 Page 1 of 17 Version 2.0

Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

This unit will provide the structure needed to achieve successful supervision and oversight of the study. We will explain the importance of an

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Good Clinical Laboratory Practice (GCLP) An international quality system for laboratories which undertake the analysis of samples from clinical trials

Document Title: Supply of Clinical Trials Investigational Material: Dispensing, Returns and Accountability

Guidance for Industry Computerized Systems Used in Clinical Investigations

ROLE OF THE RESEARCH COORDINATOR


20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany

Tomorrow s Trials: Perceived Barriers to Going Paperless Crumble in the Cloud

Good Documentation Practices

GUIDELINES FOR RETENTION OF CLINICAL TRIAL RECORDS AT INVESTIGATOR STUDY SITES

Changes to the Energy Performance of Buildings Framework. Policy update 5 Energy Performance Certificate compliance and enforcement

The Clinical Trials Regulation EU No 536/2014: and Phase I trials

Guidance for Industry

Data Governance Planning PDA 12 May 2015

Presented by Rosemarie Bell 24 April 2014

Phlexglobal Whitepaper

Biotech Concerto #3. European Clinical Trial Environment

European Forum for Good Clinical Practice Audit Working Party

TEMPLATE DATA MANAGEMENT PLAN

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

and Regulatory Aspects

Oversight of Clinical Trials in Europe - Member State perspective. Gunnar Danielsson Senior Expert Pharmaceutical Inspector

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

Guideline on good pharmacovigilance practices (GVP)

PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group

QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES

Good Clinical Practice - A Guide to Archiving

A Guide to Archiving of Electronic Records

ICRIN Seminar on EU Regulation of Clinical Trials

GOOD CLINICAL LABORATORY PRACTICE (GCLP)

Transcription:

Safeguarding public health GCP Inspection of Ti Trial Master Files DIA, 12th Conference on European Electronic Document Management/ EDM Crown copyright 2011 The materials featured within these MHRA presentation notes and delegate pack are subject to Crown copyright protection for this event. Any other copy or use of Crown copyright materials featured in this presentation, in any form or medium, is subject to prior approval of the MHRA which has Delegated Authority from Her Majesty's Stationery Office (HMSO) to administer Crown copyright for MHRA originated material. Applications should be in writing, clearly stating the proposed use/reuse of the information, and should be sent to the MHRA at the following address: Conference and Education Function, MHRA, 151 Buckingham Palace Road, London SW1W 9SZ. Fax 020 7084 3522 or e-mail speakers@mhra.gsi.gov.uk. You may not sell or resell any information reproduced to any third party without prior agreement. The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned. Slide 2 of 14 Contents The need for a Trial Master File (TMF) Organisation, Structure and Content of TMFs & Availability of TMF/eTMF Practical Considerations for inspecting Advantages of Issues relating to TMF/ (MHRA) Slide 3 of 14 1

Why do we need a Trial Master File? Adopt detailed guidelines on the documentation relating to the clinical trial that constitutes the master file [Directive 2001/20 EC] The verification of compliance with the standards of good clinical practice requires data, information and documents to be inspected, which means the competent authority conducting an official review of documents and records. [Directive 2001/20 EC] GCP PRINCIPLES: All clinical trial information shall be recorded, handled, and stored in such a way that it can be accurately reported, inter-preted and verified [Directive 2005/28 EC] The necessary procedures to secure the quality of every aspect of the trial shall be complied with [Directive 2005/28 EC] Slide 4 of 14 Organisation, Structure and Content of Trial Master Files Sponsor, Investigator and made complex by CRO use: Clarity on documentation held by CROS and contracts: a) the transfer of sponsor activities being delegated and assumed by the CRO b) how the TMF will be managed (who, where, what, when) in relation to the delegated duties and tasks. c) What will CRO retain? Will CRO records be retained by sponsor? Essential documents: ALL those documents showing the trial was in compliance with the principles and guidelines of GCP and reconstructs fully the trial events: - Generated from following organisations procedures - Not restricted to Volume 10/ICH GCP section 8 or DIA model - Risk adaptations in trial management impact on TMF records Slide 5 of 14 Organisation, Structure and Content of Trial Master Files The TMF management and structure should be established at the start of the trial and the TMF organised to facilitate inspection and management of the trial: - SOP recommended to identify all components etc of TMF - Clearly structured to account for documentation levels and the trial complexity (Global, Country, Investigator, CRO etc.) - Easy location of documents - clear and appropriate indexing system for the sections/documents. - Avoid duplication of documents. - Correspondence should be relevant and organised. - Contemporaneous - Documentations should be complete, legible, accurate, and unambiguous and signed/dated as appropriate. Keep the TMF for at least 5 years [longer for trials supporting marketing authorisations some documents for lifetime of product] Named individual responsible Slide 6 of 14 2

Availability of Trial Master Files For the inspection the sponsor should provide: - The full Trial Master File not just clinical operations documentation (unless only particular areas specified by the inspection) - For global trials, the relevant parts of the TMF for the site inspected should be available. - Need to ensure that access is readily available (and can be retrieved if archived) upon request of the competent authorities. The TMF provided should be in the form as used by the sponsor (especially if inspecting a live trial) Direct Access should be provided to all sections of the TMF (including multiple electronic systems, if applicable). Slide 7 of 14 Transfer of documents from paper into the etmf subject to QC (validated) process. Transfers should be certified for accuracy, completeness and legibility. Transfer should not conceal any physical change to the document (e.g. cut & paste to remove or add items, use of correction fluid etc.) Ability to demonstrate documents are authentic, complete and legible copies of the original documents. Controls to ensure records cannot be altered without appropriate authorisation and the creation of an audit trail for records stored electronically (or on other non-indelible media). Controls should be in place on access/use the etmf system (security). Must be able to access electronic media in future to ensure accessible and legible when in long term archive (e.g. ability to access software/hardware dependency, test restores etc.) Destruction of original paper records risk based approach Slide 8 of 14 Practical Considerations for Inspecting Inspectors NOT adverse to using, however, for and other electronic systems that include TMF documentation, there are practical considerations: Direct access to the live etmf (no super user) User friendly (including no excessive training) Availability of appropriate equipment Adequate speed for viewing documents Ability to mark documents for later reference Ability to compare documents Structure / indexing should allow easy identification of sections and documents Adequate document quality Access to the original paper records if required Ability to review the validation processes/documentation and QC of etmf etc. Slide 9 of 14 3

Advantages of can have advantages and potential benefits: - Availability of documentation globally addressing issues with access for all concerned parties (CROs etc.) - Reduces duplication, so only one version needs to exist - Reduces fragmentation of the TMF - Ability to provide access to the same type of document across all studies/sponsors/product etc. - Search features - Environmental benefits (reduces need for paper, document transit and travel for audit/inspection/trial management etc.) IN FUTURE: - Direct access to the e-tmf through secure internet links leading to Virtual GCP Inspections of TMF by inspectors based at their offices. Slide 10 of 14 Summary MHRA GCP Inspection Findings Relating to TMF & etmf (1) Organisation was unable to provide a full TMF (paper and electronic) for inspection purposes on request of the MHRA GCP inspectors. In some cases resulting in additional inspection days required All the documentation was not contained in the TMF and etmf. (e.g. was restricted to the contents of ICH E6 Section 8 documents) TMF documentation held outside the UK and documents relevant to UK trial sites was not able to be accessed by the inspectors. Failure to record the location of documents that should be in the TMF. Lack of clarity on what constituted the TMF for the trial. The paper TMF structure (poor indexing etc.) did not facilitate review to evaluate the conduct of the trial. The sponsor provided an artificial TMF, thus failed to provide adequate direct access. Staff that were put forward as system users for etmf were unable to locate documents requested by the inspector. Slide 11 of 14 Summary MHRA GCP Inspection Findings Relating to TMF & etmf (2) Failure to fully document and perform effective QC checks on documents uploaded into etmf. Incorrect documents located in the TMF and etmf. There was poor, often repetitive, sometimes incorrect labelling of files, resulting in excessive time wasted opening and closing documents in the etmf when attempting to locate documents. There was no accurate record with the details of documents sent to contractor for uploading into etmf. There was a failure to document activities to allow reconstruction of the trial conduct. The organisation did not provide adequate equipment for the inspector to review the etmf. GCP inspectors regularly give findings for documentation within the TMF not being version controlled, fully completed and signed & Dated (where document requires it). Slide 12 of 14 4

References EU Clinical Trials Directive 2001/20/EC (relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) EU GCP Directive: 2005/28/EC (laying down the principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisations of the manufacturing or importation of such products) EU Directive: 2003/63/EC (amending Directive 2001/83/EC of the European parliament and of the council of the community code relating to medicinal products for human use) Recommendation on the content of the trial master file and archiving July 2006, Volume 10, Chapter V http://ec.europa.eu/health/documents/eudralex/vol-10/ CPMP/ICH/135/95: Note for Guidance on Good Clinical Practice (ICH E6) http://www. ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html EMA GCP INSPECTORS Questions and Answers http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000072.jsp&murl=menus/regu lations/regulations.jsp&mid=wc0b01ac05800268ad DIA TMF Model http://www.diahome.org/en/homepage/edm+corner.htm Slide 13 of 14 Any Questions? Slide 14 of 14 5